Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New migraine pill NB001 heads to phase 2 trial

NCT ID NCT07577050

First seen May 13, 2026 · Last updated May 25, 2026 · Updated 4 times

Summary

This study tests whether a new drug called NB001 can quickly stop migraine pain and other bothersome symptoms. About 120 adults with migraines will receive either NB001 or a placebo. The main goal is to see if more people are pain-free and symptom-free two hours after taking the drug.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MIGRAINE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.